Epstein-Barr virus nuclear antigen 2 induces interleukin-18 receptor expression in B cells

Blood

Volumn 105, Issue 4, 2005, Pages 1632-1639

  Pagès, Franck ^b   Galon, Jérôme ^b   Karaschuk, Galina ^b   Dudziak, Diana ^b   Camus, Mathieu ^b   Lazar, Vladimir ^b   Camilleri Broët, Sophie ^b   Lagorce Pagès, Christine ^b   Lebel Binay, Sophie ^b   Laux, Gerhard ^b   Fridman, Wolf Herman ^b   Henglein, Berthold ^a  

^a CNRS   (France)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ANTIGEN 2; INTERLEUKIN 18 RECEPTOR; LATENT MEMBRANE PROTEIN 1; MYC PROTEIN; NOTCH RECEPTOR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; B LYMPHOCYTE; BURKITT LYMPHOMA; CANCER CELL CULTURE; CELL IMMORTALIZATION; CONTROLLED STUDY; DNA MICROARRAY; EPSTEIN BARR VIRUS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SIGNAL TRANSDUCTION;

EID: 13544272582     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2004-08-3196     Document Type: Article

References (72)

1. Young LS, Murray PG. Epstein-Barr virus and oncogenesis: from latent genes to tumours. Oncogene. 2003;22:5108-5121.
2. Young LS, Dawson CW, Eliopoulos AG. The expression and function of Epstein-Barr virus encoded latent genes. Mol Pathol. 2000;53:238-247.
3. Khanna R, Burrows SR. Role of cytotoxic T lymphocytes in Epstein-Barr virus-associated diseases. Annu Rev Microbiol. 2000;54:19-48.
4. Rickinson AB, Moss DJ. Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. Annu Rev Immunol. 1997;15:405-431.
5. Cordier M, Calender A, Billaud M, et al. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23. J Virol. 1990;64:1002-1013.
6. Wang F, Gregory CD, Rowe M, et al. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23. Proc Natl Acad Sci U S A. 1987;84:3452-3456.
7. Kube D, Vockerodt M, Weber O, et al. Expression of epstein-barr virus nuclear antigen 1 is associated with enhanced expression of CD25 in the Hodgkin cell line L428. J Virol. 1999;73:1630-1636.
8. Tanner JE, Alfieri C. Epstein-Barr virus induces Fas (CD95) in T cells and Fas ligand in B cells leading to T-cell apoptosis. Blood. 1999;94:3439-3447.
9. Burgstahler R, Kempkes B, Steube K, Lipp M. Expression of the chemokine receptor BLR2/EBI1 is specifically transactivated by Epstein-Barr virus nuclear antigen 2. Biochem Biophys Res Commun. 1995;215:737-743.
10. Spender LC, Cornish GH, Rowland B, Kempkes B, Farrell PJ. Direct and indirect regulation of cytokine and cell cycle proteins by EBNA-2 during Epstein-Barr virus infection. J Virol. 2001;75:3537-3546.
11. Gibbons DL, Rowe M, Cope AP, Feldmann M, Brennan FM. Lymphotoxin acts as an autocrine growth factor for Epstein-Barr virus-transformed B cells and differentiated Burkitt lymphoma cell lines. Eur J Immunol. 1994;24:1879-1885.
12. Kanda K, Kempkes B, Bornkamm GW, von Gabain A, Decker T. The Epstein-Barr virus nuclear antigen 2 (EBNA2), a protein required for B lymphocyte immortalization, induces the synthesis of type I interferon in Burkitt's lymphoma cell lines. Biol Chem. 1999;380:213-221.
13. Tosato G, Tanner J, Jones KD, Revel M, Pike SE. Identification of interleukin-6 as an autocrine growth factor for Epstein-Barr virus-immortalized B cells. J Virol. 1990;64:3033-3041.
14. Klein SC, Kube D, Abts H, Diehl V, Tesch H. Promotion of IL8, IL10, TNF alpha and TNF beta production by EBV infection. Leuk Res. 1996;20:633-636.
15. Nakagomi H, Dolcetti R, Bejarano MT, Pisa P, Kiessling R, Masucci MG. The Epstein-Barr virus latent membrane protein-1 (LMP1) induces interleukin-10 production in Burkitt lymphoma lines. Int J Cancer. 1994;57:240-244.
16. Yoshimoto T, Nagase H, Yoneto T, Inoue J, Nariuchi H. Interleukin-12 expression in B cells by transformation with Epstein-Barr virus. Biochem Biophys Res Commun. 1998;252:556-560.
17. Dinarello CA. Interleukin-18. Methods. 1999;19:121-132.
18. Pages F, Berger A, Lebel-Binay S, et al. Proinflammatory and antitumor properties of interleukin-18 in the gastrointestinal tract. Immunol Lett. 2000;75:9-14.
19. Lebel-Binay S, Thiounn N, De Pinieux G, et al. IL-18 is produced by prostate cancer cells and secreted in response to interferons. Int J Cancer. 2003;106:827-835.
20. Tanaka-Kataoka M, Kunikata T, Takayama S, et al. In vivo antiviral effect of interleukin 18 in a mouse model of vaccinia virus infection. Cytokine. 1999;11:593-599.
21. Sims JE. IL-1 and IL-18 receptors, and their extended family. Curr Opin Immunol. 2002;14:117-122.
22. Parnet P, Garka KE, Bonnert TP, Dower SK, Sims JE. IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. J Biol Chem. 1996;271:3967-3970.
23. Torigoe K, Ushio S, Okura T, et al. Purification and characterization of the human interleukin-18 receptor. J Biol Chem. 1997;272:25737-25742.
24. Born TL, Thomassen E, Bird TA, Sims JE. Cloning of a novel receptor subunit, AcPL, required for interleukin-18 signaling. J Biol Chem. 1998;273:29445-29450.
25. Nakamura S, Otani T, Okura R, et al. Expression and responsiveness of human interleukin-18 receptor (IL-18R) on hematopoietic cell lines. Leukemia. 2000;14:1052-1059.
26. Airoldi I, Gri G, Marshall JD, et al. Expression and function of IL-12 and IL-18 receptors on human tonsillar B cells. J Immunol. 2000;165:6880-6888.
27. Kunikata T, Torigoe K, Ushio S, et al. Constitutive and induced IL-18 receptor expression by various peripheral blood cell subsets as determined by anti-hIL-18R monoclonal antibody. Cell Immunol. 1998;189:135-143.
28. Setsuda J, Teruya-Feldstein J, Harris NL, et al. Interteukin-18, interferon-gamma, IP-10, and Mig expression in Epstein-Barr virus-induced infectious mononucleosis and posttransplant lymphoproliferative disease. Am J Pathol. 1999;155:257-265.
29. Yao L, Setsuda J, Sgadari C, Cherney B, Tosato G. Interleukin-18 expression induced by Epstein-Barr virus-infected cells. J Leukoc Biol. 2001;69:779-884.
30. Ehlin-Henriksson B, Manneborg-Sandlund A, Klein G. Expression of B-cell-specific markers in different Burkitt lymphoma subgroups. Int J Cancer. 1987;39:211-218.
31. Calender A, Cordier M, Billaud M, Lenoir GM. Modulation of cellular gene expression in B lymphoma cells following in vitro infection by Epstein-Barr virus (EBV). Int J Cancer. 1990;46:658-663.
32. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987;6:2743-2751.
33. Pajic A, Spitkovsky D, Christoph B, et al. Cell cycle activation by c-myc in a burkitt lymphoma model cell line. Int J Cancer. 2000;87:787-793.
34. Kempkes B, Spitkovsky D, Jansen-Durr P, et al. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2. EMBO J. 1995;14:88-96.
35. Zimber-Strobl U, Kempkes B, Marschall G, et al. Epstein-Barr virus latent membrane protein (LMP1) is not sufficient to maintain proliferation of B cells but both it and activated CD40 can prolong their survival. EMBO J. 1996;15:7070-7078.
36. Hofelmayr H, Strobl LJ, Marschall G, Bornkamm GW, Zimber-Strobl U. Activated Notch1 can transiently substitute for EBNA2 in the maintenance of proliferation of LMP1-expressing immortalized B cells. J Virol. 2001;75:2033-2040.
37. Ling PD, Hayward SD. Contribution of conserved amino acids in mediating the interaction between EBNA2 and CBF1/RBPJk. J Virol. 1995;69:1944-1950.
38. Schulze A, Zerfass K, Spitkovsky D, et al. Cell cycle regulation of the cyclin A gene promoter is mediated by a variant E2F site. Proc Natl Acad Sci U S A. 1995;92:11264-11268.
39. Le Bail O, Schmidt-Ullrich R, Israel A. Promoter analysis of the gene encoding the I kappa B-alpha/MAD3 inhibitor of NF-kappa B: positive regulation by members of the rel/NF-kappa B family. EMBO J. 1993;12:5043-5049.
40. Vanden Berghe W, Plaisance S, Boone E, et al. p38 and extracellular signal-regulated kinase mitogen-activated protein kinase pathways are required for nuclear factor-kappaB p65 transactivation mediated by tumor necrosis factor. J Biol Chem. 1998;273:3285-3290.
41. Barbulescu K, Becker C, Schlaak JF, Schmitt E, Meyer zum Buschenfelde KH, Neurath MF. IL-12 and IL-18 differentially regulate the transcriptional activity of the human IFN-gamma promoter in primary CD4+ T lymphocytes. J Immunol. 1998;160:3642-3647.
42. Zimber-Strobl U, Kremmer E, Grasser F, Marschall G, Laux G, Bornkamm GW. The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter. EMBO J. 1993;12:167-175.
43. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November, 1997. Hematol J. 2000;1:53-66.
44. Camilleri-Broet S, Camparo P, Mokhtari K, et al. Overexpression of BCL-2, BCL-X, and BAX in primary central nervous system lymphomas that occur in immunosuppressed patients. Mod Pathol. 2000;13:158-165.
45. Galon J, Franchimont D, Hiroi N, et al. Gene profiling reveals unknown enhancing and suppressive actions of glucocorticoids on immune cells. FASEB J. 2002;16:61-71.
46. Nakamura S, Otani T, Okura R, et al. Expression and responsiveness of human interieukin-18 receptor (IL-18R) on hematopoietic cell lines. Leukemia. 2000;14:1052-1059.
47. Abbot SD, Rowe M, Cadwallader K, et al. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein. J Virol. 1990;64:2126-2134.
48. Waltzer L, Logeât F, Brou C, Israel A, Sergeant A, Manet E. The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements. EMBO J. 1994;13:5633-5638.
49. Kaiser C, Laux G, Eick D, Jochner N, Bornkamm GW, Kempkes B. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2. J Virol. 1999;73:4481-4484.
50. Gordadze AV, Peng R, Tan J, et al. Notch1IC partially replaces EBNA2 function in B cells immortalized by Epstein-Barr virus. J Virol. 2001;75:5899-5912.
51. Babcock GJ, Hochberg D, Thorley-Lawson AD. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell. Immunity. 2000;13:497-506.
52. Bashir R, Luka J, Cheloha K, Chamberlain M, Hochberg F. Expression of Epstein-Barr virus proteins in primary CNS lymphoma in AIDS patients. Neurology. 1993;43:2358-2362.
53. Sinclair AJ, Palmero I, Peters G, Farrell PJ. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus. EMBO J. 1994;13:3321-3328.
54. Knutson JC. The level of c-fgr RNA is Increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization. J Virol. 1990;64:2530-2536.
55. Henkel T, Ling PD, Hayward SD, Peterson MG. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa. Science. 1994;265:92-95.
56. Laux G, Adam B, Strobl LJ, Moreau-Gachelin F. The Spi-1/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-J kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element. EMBO J. 1994;13:5624-5632.
57. Johannsen E, Koh E, Mosialos G, Tong X, Kieff E, Grossman SR. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1. J Virol. 1995;69:253-262.
58. Sjoblom A, Yang W, Palmqvist L, Jansson A, Rymo L. An ATF/CRE element mediates both EBNA2-dependent and EBNA2-independent activation of the Epstein-Barr virus LMP1 gene promoter. J Virol. 1998;72:1365-1376.
59. Tong X, Drapkin R, Yalamanchili R, Mosialos G, Kieff E. The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE. Mol Cell Biol. 1995;15:4735-4744.
60. Tong X, Drapkin R, Reinberg D, Kieff E. The 62- and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2. Proc Natl Acad Sci USA. 1995;92:3259-3263.
61. Tong X, Wang F, Thut CJ, Kieff E. The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein. J Virol. 1995;69:585-588.
62. Wu DY, Kalpana GV, Goff SP, Schubach WH. Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Ini1. J Virol. 1996;70:6020-6028.
63. Wu DY, Krumm A, Schubach WH. Promoter-specific targeting of human SWI-SNF complex by Epstein-Barr virus nuclear protein 2. J Virol. 2000;74:8893-8903.
64. Zhou S, Fujimuro M, Hsieh JJ, Chen L, Hayward SD. A role for SKIP in EBNA2 activation of CBF1-repressed promoters. J Virol. 2000;74:1939-1947.
65. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in B-cell chronic lymphocytic leukemia cells, T cells, and hematopoietic cell lines: cell-type-independent-induction of CD23, CD21, and ICAM-1. Leukemia. 1993;7:104-112.
66. Peng M, Lundgren E. Transient expression of the Epstein-Barr virus LMP1 gene in human primary B cells induces cellular activation and DNA synthesis. Oncogene. 1992;7:1775-1782.
67. Pajic A, Staege MS, Dudziak D, et al. Antagonistic effects of c-myc and Epstein-Barr virus latent genes on the phenotype of human B cells. Int J Cancer. 2001;93:810-816.
68. Yoshimoto T, Takeda K, Tanaka T, et al. IL-12 upregulates IL-18 receptor expression on T cells, Th1 cells, and B cells: synergism with IL-18 for IFN-gamma production. J Immunol. 1998;161:3400-3407.
69. Benjamin D, Sharma V, Kubin M, et al. IL-12 expression in AIDS-related lymphoma B cell lines. J Immunol. 1996;156:1626-1637.
70. Airoldi I, Guglielmino R, Carra G, et al. The interleukin-12 and interleukin-12 receptor system in normal and transformed human B lymphocytes. Haematologica. 2002;87:434-442.
71. Debets R, Timans JC, Churakowa T, et al. IL-18 receptors, their role in ligand binding and function: anti-IL-1 RAcPL antibody, a potent antagonist of IL-18. J Immunol. 2000;165:4950-4956.
72. Joseph AM, Babcock GJ, Thorley-Lawson DA. Cells expressing the Epstein-Barr virus growth program are present in and restricted to the naive B-cell subset of healthy tonsils. J Virol. 2000;74:9964-9971.